Skip to main content

Table 2 Clinical outcomes during the follow-up period

From: Impact of estimated glomerular filtration rate on long-term clinical outcomes among Chinese patients with atrial fibrillation

Outcomes Total population
n = 433
Individuals with VHDs Individuals without VHDs
n = 283
P-value
ERHA Type 1
n = 91
ERHA Type 2
n = 59
Death, n (%) 73 (16.9) 19 (20.9) 10 (16.9) 44 (15.5) 0.497
Heart failure, n (%) 24 (5.5) 1 (1.1) 7 (11.9) 16 (5.7) 0.019
ACS, n (%) 6 (1.4) 1 (1.1) 0 (0) 5 (1.8) 0.375
Hypotension, n (%) 3 (0.7) 0 (0) 0 (0) 3 (1.1) 0.278
TIA or Stroke, n (%) 39 (9.0) 6 (6.6) 1 (1.7) 32 (11.3) 0.042
VT or VF, n (%) 2 (0.5) 1 (1.1) 0 (0) 1 (0.4) 0.395
Othersa , n (%) 2 (0.5) 0 (0) 1 (1.7) 1 (0.4) 0.605
  1. Median follow-up period 3.1 (0.5–4.5) years. VHD indicates valvular heart diseases
  2. ACS acute coronary syndrome, TIA transient ischemic attack, VT ventricular tachycardia, VF ventricular fibrillation, AF atrial fibrillation
  3. aOthers includes 1 allergic dermatitis and 1 cholecystectomy